Blue Trust Inc. Raises Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Blue Trust Inc. boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 2,129.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,968 shares of the company’s stock after buying an additional 3,790 shares during the quarter. Blue Trust Inc.’s holdings in Elanco Animal Health were worth $57,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ELAN. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Elanco Animal Health in the first quarter valued at $1,226,000. Jupiter Asset Management Ltd. bought a new stake in Elanco Animal Health in the 1st quarter valued at about $4,956,000. Davidson Kempner Capital Management LP purchased a new stake in Elanco Animal Health during the second quarter valued at about $839,000. Price T Rowe Associates Inc. MD boosted its position in Elanco Animal Health by 4.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock worth $360,425,000 after purchasing an additional 852,281 shares during the period. Finally, Twin Tree Management LP increased its stake in shares of Elanco Animal Health by 134.1% in the first quarter. Twin Tree Management LP now owns 310,161 shares of the company’s stock worth $5,049,000 after purchasing an additional 177,671 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on ELAN shares. Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Barclays cut their price target on Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating for the company in a report on Monday. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

Elanco Animal Health Trading Down 1.0 %

Elanco Animal Health stock opened at $12.65 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. Elanco Animal Health Incorporated has a fifty-two week low of $8.59 and a fifty-two week high of $18.80. The stock has a market cap of $6.25 billion, a P/E ratio of -4.77, a PEG ratio of 1.32 and a beta of 1.40. The firm’s fifty day moving average price is $14.19 and its 200-day moving average price is $14.75.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 EPS. Equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons purchased 100,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. This trade represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.